These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24596374)

  • 1. Therapeutic activity of testosterone in metastatic breast cancer.
    Boni C; Pagano M; Panebianco M; Bologna A; Sierra NM; Gnoni R; Formisano D; Bisagni G
    Anticancer Res; 2014 Mar; 34(3):1287-90. PubMed ID: 24596374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute.
    Segura-González M; Quintana-Quintana M
    Med Oncol; 2015 Apr; 32(4):93. PubMed ID: 25720523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of locoregional radiotherapy in patients with metastatic breast cancer.
    Mauro GP; de Andrade Carvalho H; Stuart SR; Mano MS; Marta GN
    Breast; 2016 Aug; 28():73-8. PubMed ID: 27240169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
    Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
    Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
    Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
    Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative therapy for elderly patients with breast cancer.
    von Rueden DG; Sessions SC
    Am Surg; 1994 Jan; 60(1):72-8. PubMed ID: 8273979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients.
    Korhonen T; Kuukasjärvi T; Huhtala H; Alarmo EL; Holli K; Kallioniemi A; Pylkkänen L
    Breast; 2013 Dec; 22(6):1119-24. PubMed ID: 23863867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy in patients with distant metastatic breast cancer.
    Steinauer K; Gross MW; Huang DJ; Eppenberger-Castori S; Güth U
    Radiat Oncol; 2014 May; 9():126. PubMed ID: 24885766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
    Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer.
    Kawano A; Shimizu C; Hashimoto K; Kinoshita T; Tsuda H; Fujii H; Fujiwara Y
    Breast Cancer; 2013 Apr; 20(2):145-51. PubMed ID: 22139727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
    Tan WW; Allred JB; Moreno-Aspitia A; Northfelt DW; Ingle JN; Goetz MP; Perez EA
    Clin Breast Cancer; 2016 Apr; 16(2):82-6. PubMed ID: 26774555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Success and failure of primary medical, nonoperative management in breast cancer.
    Schmid SM; Modlasiak AA; Myrick ME; Kilic N; Viehl CT; Schötzau A; Güth U
    Ann Surg Oncol; 2011 Aug; 18(8):2166-72. PubMed ID: 21311982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.
    Keskin S; Muslumanoglu M; Saip P; Karanlık H; Guveli M; Pehlivan E; Aydoğan F; Eralp Y; Aydıner A; Yavuz E; Ozmen V; Igci A; Topuz E
    Oncology; 2011; 81(1):30-8. PubMed ID: 21912195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG).
    Ishikawa M; Takamatsu Y; Mitsuyama S; Iwakuma N; Anan K; Umeda S; Tamura K
    Breast Cancer; 2010 Apr; 17(2):131-5. PubMed ID: 19472037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.